Marker Therapeutics to Present MT-601 Data at ASH Annual Meeting
ByAinvest
Monday, Nov 3, 2025 9:16 am ET1min read
MRKR--
Marker Therapeutics announced upcoming presentations on MT-601 at the 67th ASH Annual Meeting, highlighting encouraging preliminary efficacy data from the Phase 1 APOLLO study. MT-601 demonstrated a robust safety profile with no dose-limiting toxicities or ICANS in the dose escalation cohort. The ongoing study investigates MT-601 in patients with relapsed B cell lymphomas, including those who relapsed after CAR-T cell therapy.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet